News

Abivax Announces Plans to Conduct Registered Public Offering in the United States

PARIS, FRANCE / ACCESSWIRE / August 10, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) today announced that it…

1 year ago

Virginia’s Largest Ophthalmology, Optometry Clinic, and Storefront Transitions to eClinicalWorks Vision Solutions

50+ provider Virginia Eye Institute deploys eClinicalWorks EHR and healow patient engagement solutionsWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud EHR,…

1 year ago

Altrua HealthShare Welcomes Jordan St. Cyr to Its Family as Both a Member and Ambassador for the Christian Health Share

AUSTIN, TX / ACCESSWIRE / August 10, 2023 / Altrua HealthShare has welcomed Juno Award-winning singer-songwriter Jordan St. Cyr to…

1 year ago

Lifeskills South Florida Opens New 34-Bed Fort Lauderdale Campus Providing Mental Health and Addiction Services

Responding to the growing need for detoxification services and acute mental health stabilization, Lifeskills added a campus in Ft. Lauderdale.BRENTWOOD,…

1 year ago

CorVive Athlete Soars at the World Triathlon Age Group Championships in Hamburg

PLANO, TX / ACCESSWIRE / August 10, 2023 / CorVive, a leading company in the health and wellness industry, is…

1 year ago

Imperative Care Unveils New Structure to Elevate Care for Patients with Vascular Diseases

A new business architecture connects the continuum of stroke and vascular care for patients from onset through post-acute careCAMPBELL, Calif.--(BUSINESS…

1 year ago

Elixia Health Enters Phase I Clinical Trials Market

Tampa-based site expands study capabilities and patient comfortHOLLYWOOD, FL / ACCESSWIRE / August 10, 2023 / Elixia Health, a leading…

1 year ago

Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates

Click here to register for webcastCompany plans to file its Earnings Report on August 14, 2023 on Form 10-Q for…

1 year ago

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma

Trial Results Expected in Mid-2024WOBURN, MA / ACCESSWIRE / August 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical…

1 year ago

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AMLAPVO436 Poised…

1 year ago